Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Oct 27, 2024 9:30 AM - Oct 29, 2024 6:00 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

The 21st DIA Japan Annual Meeting 2024

Toward a Well-Being Future in which Each and Every One of Us Has ‘Ikigai’


Click Here to View the Flyer

Program Overview

The theme of this year’s Annual Meeting is Toward a Well-Being Future in which Each and Every One of Us Has ‘Ikigai’. We have seen a recent increase in the number of Japanese words that are accepted around the world, and “Ikigai” has been added to this list for several years. Recent studies have shown that people who have a higher sense of purpose in life, those who feel that what is important in life makes life worth living, tend to have a lower risk of death and cardiovascular disease and have a longer healthy life expectancy. In recent years, attention has also focused on “well-being,” a state of complete physical, mental, and social well-being; the Growth Strategy Action Plan has set the goal of realizing a society in which people can experience “well-being” in Japan.

In this context, healthcare must be designed to help people remain not only physically and mentally healthy, but also socially and economically well and fulfilled. In the past, the mainstream of pharmaceutical and medical device industries has been the development of products to treat diseases. More comprehensive healthcare is required to create a world where people can live and realize “well being” by connecting with society despite living with their illnesses. This healthcare design change must create a new drug discovery ecosystem different from the past.

What people find as “Ikigai” in their life is unique to everyone, and each person has his/her own “well-being.” Therefore, to achieve a society where each person can realize his/her own “well-being” with his/her own “Ikigai,” we must bring together people from all walks of life in industry, government, academia, and the private sector – people from inside and outside of the pharmaceutical industry, and people from Asia and other countries outside of Japan.

We hope that this year’s DIA Japan Annual Meeting will provide the forum where people from all walks of life, organizations, roles, industries, and countries, can gather to discuss the co-creation of a society in which each person can realize their own unique “well-being” by creating a place where everyone can freely discuss their own thoughts without excluding or being excluded from anyone else’s ideas.

Program Committee

  • Kazuo  Nakamura, PhD
    Kazuo Nakamura, PhD CEO
  • Noriaki  Nagao, MPharm, PMP
    Noriaki Nagao, MPharm, PMP Director, Clinical Development Dept. , Pharmaceutical Division
  • Eri  Sekine
    Eri Sekine Executive Vice President
    CMIC Group, Japan
  • Tomoko  Kondo, PhD, RPh
    Tomoko Kondo, PhD, RPh Associare Professor
    Joint Research Center for Human Retrovirus Infection, Japan
    TOMONORI ABE, MSc Associate Manager
    Linical Co., Ltd., Japan
  • Kasumi  Daidoji, PhD, RPh
    Kasumi Daidoji, PhD, RPh Associate Director, Clinical Planning & Development Dept., Medical Headquarters
    Eisai Co., Ltd., Japan
  • Mayu  Fujita
    Mayu Fujita Senior Reviewer, Office of Pharmacovigilance l, office of new Drug l
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Fukagawa  Emiko
    Fukagawa Emiko Medical Center for Translational and Clinical Research
    Hiroshima University Hospital, Japan
  • Jun  Hasegawa
    Jun Hasegawa Medical solution Partner
    M3, Inc., Japan
  • Kanji  Hirai, RPh
    Kanji Hirai, RPh Director, Regulatory Policy & Intelligence, Regulatory Affair Area, Japan Dvlpmt
    MSD K.K., Japan
  • Yuki  Kai, MBA
    Yuki Kai, MBA Clinical Strategy and Resource Management Department, Clinical Development Divis
    Chugai Pharmaceutical Co., Ltd.,, Japan
  • Yusuke  Kajimoto
    Yusuke Kajimoto Oncology Scientific Affiars
    MSD K.K., Japan
  • Keiko  Katsui, PhD
    Keiko Katsui, PhD Division of Research Integrity and Social Co-Creation
    Japan Agency for Medical Research and Development (AMED), Japan
  • Atsushi  Kitamura, MS
    Atsushi Kitamura, MS Director, Clinical Development Quality
    Pfizer R&D Japan G.K., Japan
  • Reina  Kodera
    Reina Kodera Manager, Healthcare Industries Division
    Ministry of Economy, Trade and Industry (METI), Japan
  • Yuko  Kojima, RPh
    Yuko Kojima, RPh Sr. Executive Director
    Eli Lilly Japan K.K., Japan
  • Naoki  Kotani, MSc
    Naoki Kotani, MSc Pharmaceutical Science Dept.
    Chugai Pharmaceutical Co., Ltd., Japan
  • Junpei  Kozaki
    Junpei Kozaki Senior Manager, Clinical Development
    PAREXEL International Inc., Japan
  • Takeshi  Mikami
    Takeshi Mikami Sr. Statstical Prgrammer Analysit, SP&A
    Janssen: Pharmaceutical Companies of Johnson & Johnson, Japan
  • Yuko  Mitobe
    Yuko Mitobe President
    Cancer Osyaberi Cafe, Japan
  • Akira  Nakanishi
    Akira Nakanishi
    Century Medical,Inc., Japan
  • Yukiko  Nishimura, PhD, MSc
    Yukiko Nishimura, PhD, MSc President
    NPO ASrid, Japan
  • Fumitaka  Noji
    Fumitaka Noji Asscociate Director, Clinical Operations (Therapeutics and Oncology)
    Moderna Japan Co., Ltd., Japan
  • Yasuharu  Shibata, MSc
    Yasuharu Shibata, MSc Head of Clinical Data Management, Cliinical Data Management
    MSD K.K., Japan
  • Mikiko  Shitara
    Mikiko Shitara Senior Manager, Regulatory Affairs Dept.
    Alexionpharma GK, Japan
  • Sho  Suzuki
    Sho Suzuki Deputy Review Director, Office of New Drug IV
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Satoshi  Suzuki
    Satoshi Suzuki Manager, Project Management Group, Japan Portfolio & Project Management
    Pfizer R&D Japan G.K., Japan
  • Keisuke  Suzuki, PhD
    Keisuke Suzuki, PhD Director, Innovation Center for Translational Research
    National Center for Geriatrics and Gerontology, Japan
  • Yoshiko  Takagi
    Yoshiko Takagi Center for Clinical Research
    Shinshu University Hospital, Japan
  • Mitsutoshi  Toda, MBA
    Mitsutoshi Toda, MBA Senior Lead, CRM Medical Franchise Dept. Japan Medical Division
    Novartis Pharma K.K., Japan
  • Masashi  Uchida
    Masashi Uchida Senior Manager, Clinical Trial Monitoring Group
    Bristol-Myers Squibb K.K., Japan
  • Manami  Yoshida, DVM
    Manami Yoshida, DVM Associate Director, Medical Affairs – HIV & COVID-19
    Gilead Sciences K.K., Japan
  • Haruko  Yamamoto, MD, PhD
    Haruko Yamamoto, MD, PhD Director, Department of Data Science
    National Cerebral and Cardiovascular Center, Japan
  • Junichi  Nishino, MSc, RPh
    Junichi Nishino, MSc, RPh Head, Regulatory Affairs Department
    Otsuka Pharmaceutical Co., Ltd., Japan
  • Goshi  Ozawa, MS
    Goshi Ozawa, MS Representative Director & President, Japan / R&D Head
    Juniper Therapeutix K.K., Japan
  • Yukihiro  Matsuda, MSc
    Yukihiro Matsuda, MSc Director, Clinical Delivery
    ICON Clinical Research GK, Japan
  • Masaru  Iwasaki, MD, PhD
    Masaru Iwasaki, MD, PhD Vice President, Head of Center for Advancing Clinical Research (CACR)
    University of Yamanashi, Japan
  • Keiko  Oishi, MSc
    Keiko Oishi, MSc President and COO
    CMIC Group, Japan
  • Hiroshi  Kosaku, MSc
    Hiroshi Kosaku, MSc Senior Corporate Officer, Non-clinical CRO Business, Bio-CDMO Business
  • Hironobu  Saito, PhD
    Hironobu Saito, PhD Specially Appointed Professor
    Tottori University, Chromosome Egineering Research Center, Japan
  • Yil-Seob  Lee, MD, PhD
    Yil-Seob Lee, MD, PhD Professor, Dept of Clinical Pharmacology
    CHA Global clinical research center, CHA University, Korea, Republic of
  • Xiaojun (Wendy)  Yan, MD, MBA
    Xiaojun (Wendy) Yan, MD, MBA Senior Vice President, Chief Regulatory Officer
    BeiGene (Beijing) Co., Ltd., China
  • Karen  Chu, PharmD
    Karen Chu, PharmD CEO
    Harvest Integrated Research Organization (HiRO), Taiwan
  • Jing Ping  Yeo, PhD
    Jing Ping Yeo, PhD Head - Transformation
    George Clinical, Singapore
  • Steve  Engen
    Steve Engen CEO
    Renexes LLC, United States
  • Koichi  GOTO
    Koichi GOTO Deputy Manager
    CM Plus Corporation, Japan
  • Mana  Osano
    Mana Osano Member, Regulatory Affaris Department
    Otsuka Pharmaceutical Co., Ltd., Japan
  • Maki  Yoro
    Maki Yoro Office of Safety I
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Shogo  Nakamori, MBA, MSc, RPh
    Shogo Nakamori, MBA, MSc, RPh Senior Vice President & Managing Director, DIA Japan, Korea, and Singapore
    DIA, Japan

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.